Market Overview:
The global contraceptive devices market size reached US$ 12.7 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 18.7 Billion by 2027, exhibiting a growth rate (CAGR) of 6.96% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Contraceptive devices refer to various birth control tools used for preventing pregnancies and sexually transmitted diseases (STDs), such as human immunodeficiency virus (HIV) infection. Some of the commonly used contraceptive devices include condoms, diaphragms, cervical caps, sponges, vaginal rings, subdermal implants and intrauterine devices (IUD). These devices are customized for male and female user and usually contain spermicides to chemically neutralize the sperms. Certain devices also act as a physical barrier to inhibit the sperm from coming in contact with the uterus, thereby preventing insemination and minimizing the risks of infections.
www.imarcgroup.com
Note: Information in the above chart consists of dummy data and is only shown here for representation purpose. Kindly contact us for the actual market size and trends.
The increasing prevalence of STDs, such as gonorrhea, chlamydia, trichomoniasis, hepatitis B and HIV/AIDS, across the globe represents one of the key factors driving the growth of the market. Furthermore, rising awareness among the masses regarding the available alternatives for preventing unexpected pregnancies is providing a thrust to the market growth. Governments of various developed and developing nations are also implementing campaigns to spread awareness and encourage the use of effective contraceptive devices, especially in rural areas, for population management and preventing the spread of STDs. This has resulted in a significant increase in the demand for easy to use, removable and cost-effective contraceptives. In line with this, various product innovations, such as the development of non-hormonal diaphragms and medium-term vaginal rings, are anticipated to drive the market further. Product manufacturers are largely investing in extensive research and development (R&D) activities to develop variants with higher efficacy and minimal side-effects on long-term use. Other factors, including increasing consumer inclination towards delayed pregnancies, along with rising healthcare expenditures of the individuals, are anticipated to drive the market further.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global contraceptive devices market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on device type, end user and distribution channel.
Breakup by Device Type:
www.imarcgroup.com
Note: Information in the above chart consists of dummy data and is only shown here for representation purpose. Kindly contact us for the actual market size and trends.
- Condoms
- Diaphragms
- Cervical Caps
- Sponges
- Vaginal Rings
- IUDs
- Others
Breakup by End User:
Breakup by Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Stores
- Others
Breakup by Region:
To get more information on the regional analysis of this market, Request Sample
- North America
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Middle East and Africa
Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the key players being Allergan plc, Bayer AG, Church & Dwight Co., Inc., CooperSurgical Inc., Merck & Co., Mylan Inc., Pfizer Inc., Reckitt Benckiser Group plc, Teva Pharmaceutical Industries Ltd., and The Female Health Company.
Report Coverage:
Report Features |
Details |
Base Year of the Analysis |
2021 |
Historical Period |
2016-2021 |
Forecast Period |
2022-2027 |
Units |
US$ Billion |
Segment Coverage |
Device Type, End User, Distribution Channel, Region |
Region Covered |
Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered |
United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered |
Allergan plc, Bayer AG, Church & Dwight Co., Inc., CooperSurgical Inc., Merck & Co., Mylan Inc., Pfizer Inc., Reckitt Benckiser Group plc, Teva Pharmaceutical Industries Ltd., and The Female Health Company |
Customization Scope |
10% Free Customization |
Report Price and Purchase Option |
Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499 |
Post-Sale Analyst Support |
10-12 Weeks |
Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
Key Questions Answered in This Report:
- How has the global contraceptive devices market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global contraceptive devices market?
- What are the key regional markets?
- What is the breakup of the market based on the device type?
- What is the breakup of the market based on the end user?
- What is the breakup of the market based on the distribution channel?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global contraceptive devices market and who are the key players?
- What is the degree of competition in the industry?